Abstract   

References

1. Stoll G, Kleinschnitz C, Nieswandt B. Combating innate inflammation: a new paradigm for acute treatment of stroke? Ann N Y Acad Sci 2010; 1207: 149–154. [PubMed]

2. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman, AD, Lopez AD, Murray CJ. The global burden of disease study 2010. Lancet 2013;380:2053–2260. [Abstract/Full-Text]

2. Becker KJ. Modulation of the postischemic immune response to improve stroke outcome. Stroke 2010; 41: S75–78. [PubMed]

3. Molin C, Montaner J, Abilleira S, Romero F, Ibarra B, Arenillas JF, Álvarez Sabín J. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001; 32: 1079–1084. [Abstract/Full-Text]

4. Eltzschig HK, Eckle T. Ischemia and reperfusion – from mechanism to translation. Nat Med 2011, 17:1391-1401.

5. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001, 14:89-94.

6. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-e339.

7. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008, 55:310-318.

8. Xu M, Zhang HL. Death and survival of neuronal and astrocytic cells in ischemic brain injury: A role of autophagy. Acta Pharmacol. Sin 2011; 32:1089–1099. [Google Scholar]

9. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009; 40: e331–e339. [Google Scholar]

10. Carloni S. Buonocore G, Balduini W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol. Dis 2008; 32: 329–339. [Abstract/Full-Text]

11. Meloxicam official FDA information, side effects, and uses". Drugs.com. March 2010. Retrieved 17 March 2010. [Website]

12. Noble S, Balfour JA. Meloxicam. Drugs 1996; 51 (3): 424–30. [PubMed]

13. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nature Medicine 2011;11: 1391–1401.

14. Kaczorowski DJ,  Mollen K P, Edmonds R, Billiar TR. Early events in the recognition of danger signals after tissue injury. Journal of Leukocyte Biology 2008; 83: 546–552. 

15. Becker KJ. Modulation of the postischemic immune response to improve stroke outcome. Stroke 2010; 41: S75–78.

16. Choe CU, Lewerenz J, Fischer G, et al.  Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neurochem 2009; 110: 1766–1773. [PubMed]

17. Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009;40: 1849–1857. [PubMed]

18. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20:84-91. [PubMed]

19. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476. [PubMed]

20. Yousif NG, Al-Amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 2011;11:62. [PubMed]

21. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391–397. [PubMed]

22. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003;34:2543–2548. [PubMed]

23. Bhaskar PT, Hay N. The two TORCs and Akt. Dev. Cell 2007;12(4):487–502.

24. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12(2):104–7.